In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Xenon licenses chronic pain candidate XEN402 to Teva Pharmaceutical; deal terminated

Executive Summary

Xenon Pharmaceuticals Inc. (candidates targeting genetic causes of pain, anemia, and metabolic and cardiovascular diseases) has licensed Teva Pharmaceutical Industries Ltd. exclusive worldwide rights to develop and market its oral and topical compound XEN402 (TV45070; formerly XPF002), in Phase II for several types of chronic pain.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Co-Promotion
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register